Chemistry:SHEN26
From HandWiki
SHEN26 is an investigational new drug which is being evaluated by Shenzhen Kexing Pharmaceuticals for the treatment of COVID-19. It is an RNA replicase inhibitor.[1][2]
References
- ↑ "SHEN 26". AdisInsight. Springer Nature Switzerland AG. https://adisinsight.springer.com/drugs/800069791.
- ↑ "Safety, tolerability, and pharmacokinetics of the novel RdRp inhibitor SHEN26 against SARS-CoV-2: a randomized, placebo-controlled, double-blind Phase I study in healthy subjects". Expert Opinion on Investigational Drugs 33 (5): 533–542. May 2024. doi:10.1080/13543784.2024.2347302. PMID 38662639.
 |  |
